Publication | Open Access
Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission
327
Citations
60
References
2012
Year
Passive ImmunizationImmunologyImmune RegulationImmunodominanceNeurochemical BiomarkersAntibody-aided ClearanceImmune SystemImmunotherapySynaptic SignalingNeuroinflammationExperimental NeuropathologyDegenerative PathologyAutoantibodiesAntibody EngineeringNeurologyNeuroimmunologyMouse ModelMolecular NeuroscienceAutoimmune DiseaseCell TraffickingAbnormal DepositionBrain-immune InteractionHumoral ImmunityImmune FunctionCell BiologyProtective MechanismsNeurodegenerative DiseasesNeuroscienceIntracellular TraffickingMedicine
Abnormal deposition and intercellular propagation of α-synuclein plays a central role in the pathogenesis of disorders such as Parkinson's Disease (PD) and dementia with Lewy bodies (DLB). Previous studies demonstrated that immunization against α-synuclein resulted in reduced α-synuclein accumulation and synaptic loss in a transgenic (tg) mouse model, highlighting the potential for immunotherapy. However, the mechanism by which immunization prevents synucleinopathy-associated deficits remains unknown. Here, we show that antibodies against α-synuclein specifically target and aid in clearance of extracellular α-synuclein proteins by microglia, thereby preventing their actions on neighboring cells. Antibody-assisted clearance occurs mainly in microglia through the Fcγ receptor, and not in neuronal cells or astrocytes. Stereotaxic administration of antibody into the brains of α-synuclein tg mice prevented neuron-to-astroglia transmission of α-synuclein and led to increased localization of α-synuclein and the antibody in microglia. Furthermore, passive immunization with α-synuclein antibody reduced neuronal and glial accumulation of α-synuclein and ameliorated neurodegeneration and behavioral deficits associated with α-synuclein overexpression. These findings provide an underlying mechanistic basis for immunotherapy for PD/DLB and suggest extracellular forms of α-synuclein as potential therapeutic targets.
| Year | Citations | |
|---|---|---|
Page 1
Page 1